Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Mariani, Marisa ^a   He, Shiquan ^a   McHugh, Mark ^a   Andreoli, Mirko ^a   Pandya, Deep ^a   Sieber, Steven ^a   Wu, Zheyang ^b   Fiedler, Paul ^a   Shahabi, Shohreh ^a   Ferlini, Cristiano ^a  

^a DANBURY HOSPITAL   (United States)

^b Life Science and Bioengineering Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CD59 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRUPPEL LIKE FACTOR 5; MICRORNA; MICRORNA 106A; MICRORNA 125B; MICRORNA 126; MICRORNA 145; MICRORNA 17; MICRORNA 183; MICRORNA 18A; MICRORNA 200A; MICRORNA 200C; MICRORNA 203; MICRORNA 20A; MICRORNA 21; MICRORNA 27A; MICRORNA 29A; MICRORNA 30C; MICRORNA 320; MICRORNA 375; MICRORNA 532 3P; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; RANTES; UNCLASSIFIED DRUG; MESSENGER RNA; RNA; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; NANOFLUIDICS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; VERY ELDERLY; BIOSYNTHESIS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FOLLOW UP; INFORMATION PROCESSING; METABOLISM; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DATASETS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84903771932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101065     Document Type: Article

References (29)

1. Wingo PA, Ries LA, Parker SL, Heath CW Jr (1998) Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 7: 271-282. (Pubitemid 28354137)
2. Newton KF, Newman W, Hill J (2012) Review of biomarkers in colorectal cancer. Colorectal Dis 14: 3-17.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. (2010) Colorectal cancer. Lancet 375: 1030-1047.
4. Srivastava S, Gopal-Srivastava R (2002) Biomarkers in cancer screening: a public health perspective. J Nutr 132: 2471S-2475S. (Pubitemid 34848129)
5. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
6. Lee H, Flaherty P, Ji HP (2013) Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC Med Genomics 6: 54.
7. Ma Y, Zhang P, Wang F, Liu W, Yang J, et al. (2012) An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg 255: 720-730.
8. Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, et al. (2012) Gender influences the Class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res.
9. Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, et al. (2013) MiR-200c and HuR in ovarian cancer. BMC Cancer 13: 72.
10. Li L, Li H (2004) Dimension reduction methods for microarrays with application to censored survival data. Bioinformatics 20: 3406-3412. (Pubitemid 40136775)
11. Li L, Yin X (2008) Sliced inverse regression with regularizations. Biometrics 64: 124-131. (Pubitemid 351316867)
12. Pfeiffer RM, Bur E (2008) A model free approach to combining biomarkers. Biom J 50: 558-570.
13. Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39: D152-157.
14. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
15. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, et al. (2009) Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res 15: 7642-7651.
16. Hogan NM, Joyce MR, Kerin MJ (2012) MicroRNA expression in colorectal cancer. Cancer Biomark 11: 239-243.
17. Gonzalez-Gonzalez M, Garcia JG, Montero JA, Fernandez LM, Bengoechea O, et al. (2013) Genomics and proteomics approaches for biomarker discovery in sporadic colorectal cancer with metastasis. Cancer Genomics Proteomics 10: 19-25.
18. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, et al. (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15: 390-404.
19. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, et al. (2011) Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29: 4611-4619.
20. Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Sole X, et al. (2012) Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One 7: e48877.
21. Georges RB, Adwan H, Hamdi H, Hielscher T, Linnemann U, et al. (2011) The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biol Ther 12: 69-79.
22. Kansra S, Ewton DZ, Wang J, Friedman E (2000) IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. Int J Cancer 87: 373-378. (Pubitemid 30451648)
23. Baxter RC (2013) Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions. J Cell Commun Signal 7: 179-189.
24. Baxter RC (2001) Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 54: 145-148.
25. Held-Feindt J, Paredes EB, Blomer U, Seidenbecher C, Stark AM, et al. (2006) Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 118: 55-61. (Pubitemid 41681580)
26. Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ, et al. (2011) Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol 18: 2338-2347.
27. Lemos C, Sack U, Schmid F, Juneja M, Stein U (2013) Anti-metastatic treatment in colorectal cancer: targeting signaling pathways. Curr Pharm Des 19: 841-863.
28. Trovato M, Vitarelli E, Grosso M, Alesci S, Benvenga S, et al. (2004) Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors. Eur J Histochem 48: 291-297.
29. Matteucci E, Bendinelli P, Desiderio MA (2009) Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 30: 937-945.